Takeda recruit refocuses marketing, R&D on emerging markets

Takeda Pharmaceutical's pipeline needs a big boost now that its diabetes blockbuster Actos is facing generic rivals come August. So, it tapped Gates Foundation and GlaxoSmithKline ($GSK) veteran Tachi Yamada to shake up R&D. Among his moves: a new vaccines unit, new focus on developing countries and a new internal grant program. Report